Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher R M Asquith

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Nature Reviews. Drug Discovery|July 14, 2021
eEF2K: an atypical kinase target for cancerLouisa Temme, Christopher R M Asquith
Archiv Der Pharmazie|October 9, 2024
Pentathiepins are an understudied molecular prism of biological activitiesLuca Pozzetti, Christopher R M Asquith
Nature Reviews. Drug Discovery|June 27, 2020
STK19: a new target for NRAS-driven cancerChristopher R M Asquith, Louisa Temme
Nature Reviews. Drug Discovery|February 9, 2021
CDC42BPA/MRCKα: a kinase target for brain, ovarian and skin cancersMichael P East, Christopher R M Asquith
International Journal of Molecular Sciences|March 29, 2023
Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore ProfilesAndrew A Bieberich, Christopher R M Asquith
Nature Reviews. Drug Discovery|September 14, 2022
PKN3: a target in cancer metastasisLouisa Temme, Tuomo Laitinen, Christopher R M Asquith
Nature Reviews. Drug Discovery|April 26, 2020
PIP5K1A: a potential target for cancers with KRAS or TP53 mutationsMichael P East, Tuomo Laitinen, Christopher R M Asquith
Nature Reviews. Drug Discovery|March 5, 2020
PKMYT1: a forgotten member of the WEE1 familyChristopher R M Asquith, Tuomo Laitinen, Michael P East
Nature Reviews. Drug Discovery|September 10, 2021
PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disordersPei-Tzu Huang, Shirit Einav, Christopher R M Asquith
Nature Reviews. Drug Discovery|June 12, 2021
BCKDK: an emerging kinase target for metabolic diseases and cancerMichael P East, Tuomo Laitinen, Christopher R M Asquith
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Nature Reviews. Drug Discovery|July 14, 2021
eEF2K: an atypical kinase target for cancerLouisa Temme, Christopher R M Asquith
Archiv Der Pharmazie|October 9, 2024
Pentathiepins are an understudied molecular prism of biological activitiesLuca Pozzetti, Christopher R M Asquith
Nature Reviews. Drug Discovery|June 27, 2020
STK19: a new target for NRAS-driven cancerChristopher R M Asquith, Louisa Temme
Nature Reviews. Drug Discovery|February 9, 2021
CDC42BPA/MRCKα: a kinase target for brain, ovarian and skin cancersMichael P East, Christopher R M Asquith
International Journal of Molecular Sciences|March 29, 2023
Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore ProfilesAndrew A Bieberich, Christopher R M Asquith
Nature Reviews. Drug Discovery|September 14, 2022
PKN3: a target in cancer metastasisLouisa Temme, Tuomo Laitinen, Christopher R M Asquith
Nature Reviews. Drug Discovery|April 26, 2020
PIP5K1A: a potential target for cancers with KRAS or TP53 mutationsMichael P East, Tuomo Laitinen, Christopher R M Asquith
Nature Reviews. Drug Discovery|March 5, 2020
PKMYT1: a forgotten member of the WEE1 familyChristopher R M Asquith, Tuomo Laitinen, Michael P East
Nature Reviews. Drug Discovery|September 10, 2021
PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disordersPei-Tzu Huang, Shirit Einav, Christopher R M Asquith
Nature Reviews. Drug Discovery|June 12, 2021
BCKDK: an emerging kinase target for metabolic diseases and cancerMichael P East, Tuomo Laitinen, Christopher R M Asquith
Pageof 6